Moreover, the flexible antibody format further enhanced the therapeutic potential of BAFF-based TCEs, offering a promising strategy to address antigen heterogeneity and improve efficacy when treating hematologic malignancies. The gene discussed is TNFSF13B; the disease is hematologic disorder.